Therapy News and Research

RSS

Roundup: Blue Shield of Calif. drops coverage of controversial drug in breast cancer treatment; Perry presses stem cell therapy

Blue Shield of California will no longer pay for the use of the drug Avastin to treat breast cancer, a sign that support for the widely debated and expensive treatment may be eroding among health plans.

4 Oct 2011

Santaris Pharma to report new clinical data from miravirsen Phase 2a study on HCV

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA and mRNA-targeted therapies, today announced the Company will report new clinical data results from the miravirsen Phase 2a proof-of-concept study to treat patients infected with the Hepatitis C virus (HCV) in a late-breaking oral presentation session at the American Association for the Study of Liver Diseases (AASLD) 2011 annual meeting.

4 Oct 2011

NAHC statement on Senate Finance Committee report

Val J. Halamandaris, president of The National Association for Home Care and Hospice (NAHC), issued the following statement regarding the Senate Finance Committee Report on Home Health Services.

3 Oct 2011

Interactive video games appear valuable for ICU patients

Interactive video games, already known to improve motor function in recovering stroke patients, appear to safely enhance physical therapy for patients in intensive care units (ICU), new research from Johns Hopkins suggests.

3 Oct 2011

Adaptimmune announces new board appointments as clinical programmes get underway

Adaptimmune, the T cell therapy company pioneering enhanced T cell receptor-driven T cells for the treatment of cancer and infectious disease, announces two new Board appointments with immediate effect. Dr Jonathan Knowles joins the Board as a non-executive director and Dr Helen Tayton-Martin, Adaptimmune’s Chief Operating Officer, becomes an executive director.

3 Oct 2011

IMRIS unveils VISIUS Surgical Theatre

IMRIS Inc. today officially launched VISIUS Surgical Theatre, its new global product branding at the Congress of Neurological Surgeons (CNS) being held in Washington DC.

3 Oct 2011

Potential new drug could treat mixed-lineage leukaemia

A team lead by Cancer Research UK scientists have shown that a potential new drug could treat mixed-lineage leukaemia (MLL), the most common form of leukaemia in babies, according to a study published in Nature today.

3 Oct 2011

Health Canada approves Trajenta (linagliptin) for type 2 diabetes

Boehringer Ingelheim Canada and Eli Lilly Canada today announced that Health Canada has approved Trajenta (linagliptin), a new oral therapy to improve glycemic control in Canadian adults with type 2 diabetes.

3 Oct 2011

GETINGE to acquire Atrium Medical

Atrium Medical Corporation, announced today that it has signed a definitive agreement to be acquired by GETINGE GROUP of Sweden and its subsidiary, MAQUET Cardiovascular, a global leading provider of cardiovascular technologies for $680 million.

3 Oct 2011

Study compares treatment plans for CyberKnife treatment delivery system

Radiosurgery is a non-invasive medical procedure in which focused beams of high-energy X-rays target tumors and other abnormalities in the body. A single large dose of radiation is capable of ablating a lesion that might not be amenable to surgical removal. However, some radiosurgery systems, such as the CyberKnife (CK), can be relatively time-consuming because the treatment planning requires the delivery of up to several hundred cone-shaped beams to adequately cover an irregularly shaped tumor.

3 Oct 2011

Most people fall after stroke, usually at home: Study

Almost 60 per cent of people who have a stroke experience one or more falls afterwards - most often in their own homes - and some are left with serious injuries, according to a study released today at the Canadian Stroke Congress.

3 Oct 2011

Combination of P16 immunohistochemistry, DNA qPCR can accurately detect oropharyngeal cancer

Researchers have determined that a combination of P16 immunohistochemistry and DNA qPCR to test for viral E6 can accurately determine the oropharyngeal squamous cell carcinoma, a form of head and neck cancer, which derive from HPV16, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

3 Oct 2011

IBA offers full line of Proton Therapy solutions for cancer specialty centers

IBA Particle Therapy now offers a range of Proton Therapy solutions for cancer specialty centers planning to treat from 250 to 2,000 patients annually with protons.

From Elekta 3 Oct 2011

First clinical implementation of RayStation at MGH

RaySearch Laboratories AB announces that the first cancer patient has been treated using a treatment plan created with RaySearch's treatment planning system RayStation. The treatment was carried out at the Massachusetts General Hospital Radiation Oncology Department.

From Elekta 3 Oct 2011

Allied Health Professionals, RNs ratify new three-year contract agreement

More than 3,000 Registered Nurses and Allied Health Professionals working in 10 of Ontario's Community Care Access Centres (CCACs) have voted to ratify a new three-year contract.

3 Oct 2011

Pace Homecare acquires Sarnia-Lambton Physiotherapy

Pace Homecare is pleased to announce the acquisition of Sarnia-Lambton Physiotherapy, a home healthcare service provider located in Sarnia.

3 Oct 2011

Prostate cancer medicine deemed too-expensive by NHS

A drug used in therapy of prostate cancer that extends the lives of men with advanced prostate cancer is too expensive for use on the NHS, according to draft guidance. The drug has been shown to extend the lives of men with advanced prostate cancer by around 10 weeks.

2 Oct 2011

Tight blood sugar control fails to improve memory in diabetics

A new study has shown that those with type 2 diabetes do not show slowing of the decline in thinking skills with intense blood sugar control. In fact such intense therapy raises risk of death.

2 Oct 2011

National Healing to merge with Diversified Clinical Services

National Healing Corporation, a provider of wound and disease management solutions for hospitals, and Diversified Clinical Services, also a provider of specialized wound care management services to hospitals, today announced that they have signed a definitive agreement under which the two companies will merge.

1 Oct 2011

The US Oncology Network affiliate treats advanced prostate cancer patients with PROVENGE

David, a 67-year-old father of three and soon to be first-time grandfather, felt too young to be diagnosed with prostate cancer. "I felt great," he said. "I had no symptoms." David, under the advisement of his oncologist, decided to be treated with PROVENGE (sipuleucel-T), the first in a new therapeutic class known as autologous cellular immunotherapies.

1 Oct 2011